3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Cyclophosphamide
40
fludarabine
36
fludarabine phosphate
28
Tacrolimus
20
Whole-Body Irradiation
18
Mycophenolic Acid
18
Busulfan
18
Melphalan
16
thymoglobulin
14
Rituximab
13
Antilymphocyte Serum
12
venetoclax
11
Thiotepa
10
Nivolumab
9
Methotrexate
9
Granulocyte Colony-Stimulating Factor
9
Stem Cell Transplantation
8
Peripheral Blood Stem Cell Transplantation
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Cytarabine
7
Azacitidine
7
AP 1903 reagent
7
Filgrastim
6
Dexamethasone
6
aldesleukin
5
Mesna
5
Ipilimumab
5
Interleukin-2
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Clavulanic Acid
×
Lymphoid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled